Step 1 topics → Immunology → Calcineurin Inhibitors and mTOR Inhibitors

Calcineurin Inhibitors and mTOR Inhibitors

USMLE Step 1 trap: Confuses the intracellular binding proteins for cyclosporine vs. tacrolimus. Cyclosporine binds cyclophilin, while tacrolimus binds FKBP-12; both complexes then inhibit calcineurin.

Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are the backbone of transplant immunosuppression and show up repeatedly on USMLE Step 1 — both in straightforward mechanism questions and in clinical vignettes asking you to identify drug toxicity or drug interactions. The core concept is that these drugs all suppress T cell activation, but they do it at different steps: calcineurin inhibitors block IL-2 transcription, while mTOR inhibitors block IL-2 receptor signaling downstream. That distinction is the most tested angle.

The tricky part is that students often lump these drugs together as 'immunosuppressants that block IL-2' without tracking the mechanistic differences. USMLE Step 1 exploits exactly that laziness. You need to know not just what each drug does, but which intracellular protein it binds (cyclophilin vs. FKBP-12), where in the IL-2 pathway it acts, and what its unique toxicity profile is. A vignette about a post-transplant patient with rising creatinine is pointing you toward calcineurin inhibitors — not sirolimus.

The other high-yield trap is CYP3A4. Students see 'drug interaction' and assume the calcineurin inhibitors are inhibitors of CYP3A4 — but they're substrates, not inhibitors. That flipped mental model causes wrong answers on drug-drug interaction questions. Get the direction right: other drugs change cyclosporine/tacrolimus levels, not the other way around.

From real student decks
57%have cards covering this topic
41%have mature cards

Common misconceptions

Common mistake
Wrong: Cyclosporine and tacrolimus bind the same intracellular protein (cyclophilin) to inhibit calcineurin.
Right: Cyclosporine binds cyclophilin, while tacrolimus binds FKBP-12; both complexes then inhibit calcineurin.
Both cyclosporine and tacrolimus ultimately inhibit calcineurin, so it's tempting to think they work identically — but the intracellular binding proteins are different. Cyclosporine binds cyclophilin; tacrolimus binds FKBP-12. This matters because USMLE Step 1 will ask you to match the drug to its binding protein, and 'FKBP' stands for FK-binding protein (FK = FK506 = tacrolimus). Remember: tacrolimus → FKBP-12; cyclosporine → cyclophilin. The downstream target (calcineurin) is the same, but the upstream receptor is distinct.
Common mistake
Wrong: Sirolimus blocks IL-2 production like calcineurin inhibitors do.
Right: Sirolimus blocks the IL-2 receptor signaling pathway downstream (mTOR), not IL-2 transcription itself.
Calcineurin inhibitors prevent the T cell from ever making IL-2 in the first place — they block transcription. Sirolimus works at a completely different step: the T cell has already made and received the IL-2 signal, but sirolimus blocks mTOR, which is required for the cell to actually proliferate in response to that signal. Think of it as: calcineurin inhibitors cut off the 'go' message, while sirolimus jams the engine that responds to the message.
Common mistake
Wrong: Sirolimus is nephrotoxic like cyclosporine and tacrolimus.
Right: Nephrotoxicity is a hallmark toxicity of calcineurin inhibitors (cyclosporine > tacrolimus), not sirolimus; sirolimus causes hyperlipidemia and impaired wound healing instead.
Nephrotoxicity is one of the most clinically significant toxicities of cyclosporine and tacrolimus — it's a direct effect of calcineurin inhibition on renal vasculature (afferent arteriolar constriction). Sirolimus does not cause this. In fact, sirolimus is sometimes used in transplant regimens specifically to spare the kidney. What sirolimus causes instead is hyperlipidemia and poor wound healing — useful to remember because a post-transplant patient with a healing complication or high triglycerides points you toward sirolimus, not a calcineurin inhibitor.
Common mistake
Wrong: Calcineurin inhibitors directly inhibit CYP3A4 enzymes.
Right: Calcineurin inhibitors are substrates of CYP3A4, so CYP3A4 inducers/inhibitors alter their levels rather than the drugs themselves inhibiting CYP3A4.
The key word is 'substrate,' not 'inhibitor.' Cyclosporine and tacrolimus are broken down by CYP3A4, which means other drugs control their blood levels. A CYP3A4 inducer (like rifampin) speeds up metabolism → lower drug levels → risk of rejection. A CYP3A4 inhibitor (like fluconazole) slows metabolism → higher drug levels → toxicity. The calcineurin inhibitors are passengers in this system, not drivers — they don't meaningfully inhibit CYP3A4 themselves.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the full mechanism of calcineurin inhibitors: cyclosporine binds cyclophilin, tacrolimus binds FKBP-12, and both drug-protein complexes then inhibit calcineurin, which prevents NFAT dephosphorylation and thus blocks IL-2 gene transcription.
  2. Know that sirolimus (rapamycin) also binds FKBP-12, but the sirolimus-FKBP-12 complex inhibits mTOR rather than calcineurin — blocking T cell proliferation in response to IL-2 signaling, not IL-2 production itself.
  3. Know the toxicity profiles cold: nephrotoxicity and hypertension for calcineurin inhibitors (cyclosporine also causes gingival hyperplasia and hirsutism; tacrolimus causes more neurotoxicity and diabetes); sirolimus causes hyperlipidemia and impaired wound healing but is NOT nephrotoxic.
  4. Understand that calcineurin inhibitors are CYP3A4 substrates — so drugs that induce CYP3A4 (rifampin, phenytoin) lower their levels and risk rejection, while CYP3A4 inhibitors (azole antifungals, macrolides) raise their levels and increase toxicity risk.

Can you avoid these mistakes?

A transplant patient on cyclosporine is started on rifampin for latent TB. Two weeks later, labs show signs of early graft rejection. What is the pharmacokinetic explanation, and what would you expect if fluconazole were added instead?
A transplant patient is switched from tacrolimus to sirolimus to protect kidney function. Both drugs bind FKBP-12. A classmate says the switch won't matter immunologically because the intracellular binding protein is the same. What is wrong with that reasoning — what is the actual downstream difference in their mechanisms, and at which step in T cell activation does each drug intervene?
A post-renal-transplant patient on immunosuppression develops a creatinine of 2.8 mg/dL (baseline 1.0), hypertension, and gingival overgrowth. Which drug is most likely responsible, and what is the mechanism of its renal toxicity?
You are building a transplant regimen and want to minimize nephrotoxicity while still preventing T cell proliferation. Which class of drug would you favor, and what side effects should you counsel the patient about instead?

Related topics

T Cell Activation and Costimulation Thymus and T Cell Maturation Spleen Architecture and Function Lymph Node and MALT Architecture Innate Immune Cells Overview

See how your Anki deck covers this topic.

Upload your deck for a free audit →